
The episode focuses on Ireland’s upcoming retail‑investment scheme, a government‑backed savings account expected to roll out in early 2025. Designed to address the €170 billion sitting in near‑zero‑interest current accounts, the plan aims to redirect household cash into stocks, bonds, or mixed funds with favorable tax treatment. The proposal borrows heavily from Sweden’s SSIA model, offering a €28,000 tax‑free allowance and a modest annual levy tied to the state borrowing rate—roughly 1 percent. Contributions can be made via monthly direct debits or lump‑sum deposits, and the account will be administered by banks, insurance firms, and potentially fintech players like Revolut, eliminating the need for individual tax filings. Dave Quinn highlights the cultural hurdle: decades of loss during the 2008 crash have left Irish savers wary of equities, preferring property or cash. He notes that the current tax rate on insurance‑linked investments sits at 38 percent, making the new scheme a dramatic improvement in after‑tax returns. If successful, the initiative could increase retail participation, provide a new source of capital for Irish enterprises, and narrow the gap between Europe’s savings surplus and its under‑invested markets. It also sets a precedent for future state‑sponsored funds targeting green energy or infrastructure projects.

Ireland is preparing to launch a new investment account next year, modeled after Sweden’s popular tax‑advantaged scheme. The proposal promises a €28,000 tax‑free allowance and a low, flat tax on the remaining balance. Under the four guiding principles, investors will pay...

The video tackles the challenge of identifying disruptive forces before they upend an industry, using artificial intelligence as the metaphorical dragon looming over SaaS firms. It argues that most disruptors remain invisible until they fundamentally alter the tools and processes...

The episode flips the usual investment narrative, focusing on why investors should actively identify red flags that keep a stock off their watchlist. Host Jared explains that while revenue graphs and profit trends dominate most discussions, a disciplined “no‑fly list” of...

Telix Pharmaceuticals, an Australian biotech specializing in radiopharmaceutical diagnostics and therapeutics, has posted explosive revenue growth over the past five years. Revenue climbed from A$4 million in FY2020 to A$5.5 million in FY2021, then surged to A$109 million in FY2022, A$333 million in FY2023, A$516 million...

Supply Network Limited (SNL) is presented as a hidden gem in Australia’s trucking sector, offering a specialised parts‑supply service for heavy‑duty vehicles rather than a conventional auto shop. The company’s competitive edge lies in deep technical expertise, rapid “parts interpreting” that...